LC/MS Analysis of Antiarrhythmic Drugs and Metabolites in Plasma on Ascentis® Express HILIC following Sample Prep using HybridSPE®-Phospholipid

LC/MS Analysis of Antiarrhythmic Drugs and Metabolites in Plasma on Ascentis® Express HILIC following Sample Prep using HybridSPE®-Phospholipid

Conditions

sample preparation SPE (Solid Phase Extraction)
sample/matrix rabbit plasma, unfiltered K2-EDTA, spiked with each compound at 100 ng/mL (3:1, plasma:1% formic acid in acetonitrile)
SPE tube/cartridge HybridSPE-Phospholipid, 96-well plate (575656-U)
sample addition to each well add 100 µl plasma, followed by a 300 µl of 1% formic acid in acetonitrile
elution collect, filtrate and analyze directly.
column Ascentis Express HILIC, 10 cm x 2.1 mm I.D., 2.7 µm particles (53939-U)
column temp. 35 C
mobile phase [A] 5 mM ammonium formate; [B] 5 mM ammonium formate in acetonitrile, 5:95 (A:B), adjusted to pH 7.0 with formic acid
flow rate 0.4 ml/min
pressure 1305 psi (90 bar)
injection 0.5 µl
detector ESI+, 100-1000 m/z

Description

Analysis Note This application shows the extraction and analysis of antiarrhythmic cardiac drugs in plasma samples using LC/MS/MS. HILIC chromatography on Ascentis Express along with a selective sample preparation using HybridSPE-Phospholipid provided sensitivity and resolution. The highest grade LC-MS solvents were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.
Categories Analytical Chromatography, SPE Applications, Clinical, antiarrhythmic drugs, cardiac drugs, Antiarrhythmic drugs, Cardiac Drugs, Cardiac drugs
Featured Industry Clinical
Legal Information Ascentis is a registered trademark of Sigma-Aldrich Co. LLC, HybridSPE is a registered trademark of Sigma-Aldrich Co. LLC
suitability application for HPLC

Materials

     
Related Links